News

Pharmaceutical Technology13h
EC approves argenx’s efgartigimod alfa for CIDP treatment
The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.
Pharmabiz15h
EMA recommends marketing authorization to Cordex Biologics’ new stem cell therapy, Zemcelpro to treat patients with blood cancers
EMA recommends marketing authorization to Cordex Biologics’ new stem cell therapy, Zemcelpro to treat patients with blood cancers: Amsterdam, The Netherlands Monday, June 23, 20 ...